---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003690"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-07-29T20:05:46+00:00"
generated_at: "2026-07-29T20:07:36.611839+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion initiates Phase 2/3 trial of SIL204 in pancreatic cancer at Tel Aviv Sourasky Medical Center

## Summary
- First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.
- Phase 2/3 trial of SIL204 (siRNA) for locally advanced pancreatic cancer; follows regulatory approvals from Israeli MoH and German BfArM.
- Trial includes safety run-in (~18 patients) then randomized cohort (~166 patients); dual-route administration (intratumoral + systemic).
- Additional Israeli and German sites expected to join in coming months; first patient dosing anticipated as next milestone.
- SIL204 targets broad range of KRAS mutations; KRAS mutations present in ~90% of pancreatic cancers.

## SEC filing metadata
- accession: 0001178913-26-003690
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-07-29T20:05:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/0001178913-26-003690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/zk2635763.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003690
- JSON: https://secwatch.observer/filing/0001178913-26-003690.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.